-
NMPA Announcement on Issues Pertaining to Online Application for Drug Registration Affairs
2020-12-28
The NMPA has enabled and officially launched on January 1, 2021 the online application module for drug registration affairs.
-
SAMR Released the Provisions for the Lot Release of Biological Products
2020-12-21
NMPA drafted the Provisions for the Lot Release of Biological Products (hereinafter referred to as the Provisions ).
-
Center for Drug Evaluation of NMPA Announced on Issuing the Administrative Measures for Communication of Drug R&D and Technical Review
2020-12-11
The Center for Drug Evaluation organized the revision of the Administrative Measures for Communication of Drug R&D and Technical Review, been released with NMPA's examination and approval for implementation as from December 10, 2020.
-
Announcement of NMPA and General Administration of Customs on the Establishment of Changchun Airport as a Drug Import Port
2021-06-15
According to the Drug Administration Law of the People's Republic of China, upon approval of the State Council, NMPA and General Administration of Customs agree to establish Changchun Airport as a drug import port.
-
NMPA Announcement on Adding the Medication Information for Children to the Package Inserts of Haloperidol Tablets and Other Varieties
2021-05-31
In order to better meet the clinical medication needs of children, upon the study and demonstration, package inserts of Haloperidol Tablets and other varieties may be added with the children users and dosage and usage for children according to the requirements.
-
NMPA Announcement on the Cancellation of Registration Certificates for 283 Drugs including Megestrol Acetate Dispersible Tablets
2021-05-24
According to the Regulations for the Implementation of the Drug Administration Law of the People's Republic of China and the Provisions for Drug Registration, NMPA has decided to cancel the registration certificate of 283 drugs including Megestrol Acetate Dispersible Tablets.
